NCT00482053: Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT |
|
|
| Terminated | 2 | 3 | US | Autologous hematopoietic stem cell transplantation (auto-HSCT), Autologous peripheral blood progenitor cell (PBPC) transplantation, Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Allogeneic peripheral blood progenitor cell (PBPC) transplantation, Total lymphoid irradiation (TLI), Rituximab, Rituxan, Mabthera, Carmustine, BCNU, BiCNU, Etoposide, Eposin, Etopophos, Vepesid, VP-16, Filgrastim, Granulocyte colony-stimulating factor (G-CSF, GCSF), Colony-stimulating factor 3 (CSF-3), Anti-thymocyte globulin (ATG), Cyclosporine, Cyclosporin, CSP, Mycophenolate mofetil (MMF), CellCept, Cyclophosphamide, Cytoxan, Neosar, Acetaminophen, Tylenol, Diphenhydramine, Benadryl, Hydrocortisone, Cortef, Methylprednisolone, Solu-Medrol | Stanford University | Lymphoma, B-cell, Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma (DLBCL), Malignant Lymphoma, Non-Hodgkin | 05/10 | 05/10 | | |
NCT03842696: Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation |
|
|
| Recruiting | 1/2 | 49 | US | Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine), Methotrexate, Mycophenolate Mofetil (MMF), Cyclophosphamide | University of Michigan Rogel Cancer Center, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS) | Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia, Blastic Phase, Myelodysplastic Syndromes, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non Hodgkin Lymphoma, Graft Vs Host Disease, Graft-versus-host-disease | 06/25 | 06/26 | | |
